Tarpan's Douglas Abel on BBC World Service Business Report
Feb 23, 2005
NEW YORK, FEBRUARY 23, 2005 ? Douglas Abel, CEO of Tarpan Therapeutics, Inc. ("Tarpan"), participated in a roundtable discussion regarding the U.S. pharmaceutical industry for the BBC World Service Business Report. Mr. Abel is expected to become CEO of Manhattan Pharmaceuticals (OTC BB: MHTT) after the Company finalizes current acquisition negotiations with Tarpan. The BBC World Service Business Report is airing on BBC affiliate radio stations worldwide throughout the week.
In light of the recent creation of the U.S. Food and Drug Administration's Drug Safety Oversight Board, Mr. Abel commended the agency's step towards greater openness while urging a balanced approach to the regulatory process that takes into account both safety concerns and patients' needs for improved therapies.
"Certainly there are inherent conflicts in every business, but in our situation, it is in our best interest to have public information available, make decisions quickly and appropriately and walk away from drugs that cause?problems," commented Mr. Abel on the program.
A webcast of the program is available through Friday, February 25, on the BBC World Service Web site: www.bbc.co.uk/worldservice/programmes/world_business_review.shtml.
Background on Doug Abel
Prior to becoming President and CEO of Tarpan, Mr. Abel served as Vice President of the Dermatology Business Unit at Biogen Idec. While at Biogen Idec, he led the creation of the U.S. dermatology commercial operation, building the team from two to 100 employees to support the launch of AMEVIVE(R). Prior to joining Biogen Idec, Mr. Abel was Director of Marketing for BOTOX(R) at Allergan Pharmaceuticals, a position he achieved after graduating from a number of progressive sales and marketing roles in Allergan's dermatology, ophthalmology, and neurology businesses. Mr. Abel received his A.B. in Chemistry from Lafayette College and an M.B.A. from Temple University.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (http://www.manhattanpharma.com/), a development stage pharmaceutical company, acquires and develops proprietary prescription drug candidates for large, underserved patient populations. In view of the worldwide obesity epidemic, the Company is developing Oleoyl estrone, an orally administered novel therapeutic for weight loss. The Company is also developing a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.